GC Genome Corporation (KOSDAQ:340450)

GC Genome Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	37,052	35,118	6,528	3,637	13,637	10,743
Short-Term Investments	5,000	5,000	-	5,000	4,000	15,000
Cash & Short-Term Investments	42,052	40,118	6,528	8,637	17,637	25,743
Cash Growth	-12.01%	514.60%	-24.42%	-51.03%	-31.49%	-12.45%
Accounts Receivable	7,560	6,996	5,439	4,307	4,221	3,702
Other Receivables	1,719	1,336	12.94	65.78	325.42	71
Receivables	9,279	8,332	5,452	4,373	4,546	3,773
Inventory	2,363	1,997	1,219	1,152	1,200	598.2
Prepaid Expenses	318.96	373.86	371.57	292.15	697.09	126.16
Other Current Assets	163.6	149.05	93.33	96.29	40.37	30.69
Total Current Assets	54,176	50,970	13,663	14,550	24,120	30,271
Property, Plant & Equipment	12,038	12,254	14,918	18,759	18,094	8,293
Long-Term Investments	17,861	17,381	7,823	6,103	3,231	1,648
Other Intangible Assets	532.53	528.85	526.09	533.37	577.52	617.6
Long-Term Accounts Receivable	-0	-0	0	-0	0	0
Long-Term Deferred Tax Assets	915.53	857.03	634.11	680.04	163.81	-
Other Long-Term Assets	2,305	2,635	3,058	2,194	2,709	1,601
Total Assets	87,827	84,627	40,622	42,819	48,896	42,431

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1,078	-	-	851.58	1,311	1,293
Accrued Expenses	1,238	542.25	383.28	840.06	1,830	1,185
Short-Term Debt	-	-	-	6,556	-	-
Current Portion of Leases	852.43	833.8	792.17	802.31	997.42	685.06
Current Income Taxes Payable	181.1	220.89	-	-	-	-
Current Unearned Revenue	290.08	662.1	1,503	941.6	1,218	1,065
Other Current Liabilities	943.46	482.23	521.2	2,986	5,036	485.16
Total Current Liabilities	4,583	2,741	3,199	12,978	10,393	4,714
Long-Term Debt	-	-	-	-	5,819	12,913
Long-Term Leases	2,921	3,185	3,878	4,398	3,787	508.18
Long-Term Deferred Tax Liabilities	-	-	-	-	-	9
Other Long-Term Liabilities	455.73	428.26	465.2	395.84	2,312	5,320
Total Liabilities	7,960	6,354	7,543	17,772	22,311	23,464

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	11,825	11,825	9,778	9,067	9,067	8,000
Additional Paid-In Capital	48,255	68,841	29,865	21,036	21,010	10,475
Retained Earnings	20,449	-1,146	-5,281	-3,964	-3,244	491.96
Comprehensive Income & Other	-661.8	-1,248	-1,282	-1,091	-247.95	-
Shareholders' Equity	79,867	78,273	33,080	25,048	26,585	18,967
Total Liabilities & Equity	87,827	84,627	40,622	42,819	48,896	42,431

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	3,774	4,018	4,670	11,757	10,604	14,106
Net Cash (Debt)	38,278	36,099	1,857	-3,120	7,033	11,636
Net Cash Growth	-11.80%	1843.62%	-	-	-39.56%	-31.71%
Net Cash Per Share	1624.37	1647.49	101.96	-170.15	435.45	727.46
Filing Date Shares Outstanding	23.65	23.65	18.22	18.34	16.15	16
Total Common Shares Outstanding	23.65	23.65	18.22	18.34	16.15	16
Working Capital	49,593	48,229	10,464	1,572	13,728	25,557
Book Value Per Share	3376.93	3309.51	1815.96	1366.01	1646.07	1185.74
Tangible Book Value	79,335	77,744	32,554	24,514	26,008	18,349
Tangible Book Value Per Share	3354.42	3287.15	1787.08	1336.92	1610.31	1147.13
Buildings	3,822	6,914	7,142	7,727	6,810	1,111
Machinery	4,620	12,650	12,814	13,055	11,332	9,800
Construction In Progress	-	-	-	-	77.14	-

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 18, 2026

Data Sources Report a data error